18F-FDG PET/CT Imaging for an Early Assessment of Response to Sunitinib in Metastatic Renal Carcinoma: Preliminary Study

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Biotherapy and Radiopharmaceuticals

• Publication date

  2009-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/cbr.2008.0527PMID 19243256
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy

  2008cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.

  2007cited by this paper
• Meta-análisis sobre el rendimiento diagnóstico de la tomografía por emisión de positrones con 18F-FDG en el carcinoma de células renales

  2007cited by this paper
• [Meta-analysis of the diagnostic performance of 18F-FDG PET in renal cell carcinoma].

  2007cited by this paper
• Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

  2007cited by this paper
• Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

  2007cited by this paper
• The value of PET-CT (positron emission tomography) in the treatment of metastatic renal cell carcinoma with sorafenib

  2007cited by this paper
• Imaging in metastatic renal cell carcinoma.

  2007cited by this paper
• The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma

  2007cited by this paper
• Biomarkers for Monitoring Antiangiogenic Therapy

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• [New entities in pathological classification and new therapeutic options in renal cell carcinoma].

  2006cited by this paper
• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

  2006cited by this paper
• Monitoring chemotherapy and radiotherapy of solid tumors

  2006cited by this paper
• Nouveautés anatomopathologiques et évolution des thérapeutiques actuelles dans les cancers du rein

  2006cited by this paper
• Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

  2006cited by this paper
• Kidney cancer: identification of novel targets for therapy.

  2006cited by this paper
• Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.

  2006cited by this paper
• Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.

  2005cited by this paper
• Renal-cell carcinoma.

  2005cited by this paper
• Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie

  2005cited by this paper
• Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma

  2004cited by this paper
• The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer

  2004cited by this paper
• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

  2003cited by this paper
• 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

  2003cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

  1999cited by this paper
• Renal-cell carcinoma.

  1996cited by this paper
• Renal cell carcinoma.

  1956cited by this paper

• Nuclear Imaging in Renal Cell Carcinoma: Current Evidence and Clinical Applications

  2026cites this paper
• Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [18F]FDG PET/CT

  2021cites this paper
• Non-invasive molecular imaging of kidney diseases

  2021cites this paper
• Response Assessment and Follow-Up by Imaging in GU Tumours

  2020cites this paper
• Prognostic significance of basal 18F-FDG PET / CT maximum standardized uptake value in patients with metastatic renal cell carcinoma who were treated with sunitinib.

  2020cites this paper
• Therapeutic Efficacy of Tyrosine Kinase Inhibitors Treatment for Metastatic Renal Cell Carcinoma Using 18F-FDG PET/CT

  2019cites this paper
• Molecular Imaging for Renal Cell Carcinoma

  2019cites this paper
• Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and 99mTc-MDP Bone Scan in a Prospective Clinical Trial

  2019cites this paper
• Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab

  2019cites this paper
• Nuclear Medicine Applications in Diagnosis of Urological Tumors

  2019cites this paper
• FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma

  2018cites this paper
• Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study

  2017cites this paper
• Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation

  2017cites this paper
• Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F–Fluorodeoxyglucose (18F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study

  2017cites this paper
• The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy

  2017cites this paper
• Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer

  2017cites this paper
• Predictive Value of 18F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib

  2017cites this paper
• Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti–Vascular Endothelial Growth Factor–Targeted Agents

  2017cites this paper
• Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors

  2017cites this paper
• Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma

  2016cites this paper
• FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma

  2016cites this paper
• Update on advances in molecular PET in urological oncology

  2016cites this paper
• Imaging Studies in Metastatic Urogenital Cancer Patients Undergoing Systemic Therapy: Recommendations of a Multidisciplinary Consensus Meeting of the Association of Urological Oncology of the German Cancer Society

  2016cites this paper
• [Positron-emission tomography in urooncology].

  2015cites this paper
• FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma

  2015cites this paper
• Management of urological malignancies: Has positron emission tomography/computed tomography made a difference?

  2015cites this paper
• Positronenemissionstomographie bei urologischen Tumorerkrankungen

  2015cites this paper
• Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

  2014cites this paper
• Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer

  2014cites this paper
• The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma

  2014cites this paper
• Detecting functional changes with [18F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy

  2014cites this paper
• Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis

  2014cites this paper
• Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations.

  2014cites this paper
• Functional Imaging of Renal Cell Carcinoma

  2014cites this paper
• The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ

  2014cites this paper
• Kidney and Bladder Cancer

  2013cites this paper
• Utilizing Positron Emission Tomography to Detect Functional Changes Following Drug Therapy in a Renal Cell Carcinoma Mouse Model

  2013cites this paper
• Detection of Rapalog-Mediated Therapeutic Response in Renal Cancer Xenografts Using 64Cu-bevacizumab ImmunoPET

  2013cites this paper
• Medikamentöse Tumortherapie urogenitaler Malignome

  2013cites this paper
• Evaluation of cancer treatment in the abdomen: Trends and advances.

  2013cites this paper
• Sorafenib in advanced iodine‐refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG‐PET

  2013cites this paper
• Diagnostic Kidney Imaging

  2012cites this paper
• Stellenwert der Positronenemissionstomographie bei urologischen Tumoren

  2012cites this paper
• Spectrum of malignant renal and urinary bladder tumors on 18F-FDG PET/CT: a pictorial essay.

  2012cites this paper
• PET/CT in renal and bladder cancers

  2012cites this paper
• Experience with sunitinib in the treatment of metastatic renal cell carcinoma

  2012cites this paper
• Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer

  2012cites this paper
• Potential role of 124 I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer

  2012cites this paper
• Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.

  2012cites this paper
• Molecular imaging of the small renal mass.

  2011cites this paper
• Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications.

  2011cites this paper
• Imaging in renal cell carcinoma.

  2011cites this paper
• Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.

  2011cites this paper
• FDG PET/CT in Detection of Adrenal Metastasis in Patients With Renal Cell Carcinoma

  2011cites this paper
• Better Late than Early: FDG-PET Imaging in Metastatic Renal Cell Carcinoma

  2011cites this paper
• Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer

  2011cites this paper
• Re: Combined Positron Emission Tomography/Computed Tomography in Sunitinib Therapy Assessment of Patients With Metastatic Renal Cell Carcinoma

  2011cites this paper
• Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study

  2011cites this paper
• Kanser FDG PET/CT görüntülemesinde olası yanlış pozitif aktif akciğer-dışı tüberküloz lezyonları

  2010cites this paper
• Targeted therapies in renal cell cancer: recent developments in imaging

  2010influential citation
• Potential of imaging biomarkers for characterization of renal masses

  2010cites this paper
• Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

  2010cites this paper
• Role of FDG PET-CT in recurrent renal cell carcinoma

  2010cites this paper
• Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma

  2010cites this paper
• Imaging of Renal Cell Carcinoma: State of the Art and Recent Advances

  2010cites this paper
• Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report

  2010cites this paper
• Stable disease in renal cell carcinoma after using signal transduction inhibitors.

  2010cites this paper
• Evaluation of Response to Multikinase Inhibitor in Metastatic Renal Cell Carcinoma by FDG PET/Contrast-Enhanced CT

  2010cites this paper
• Functional imaging of renal cell carcinoma

  2010cites this paper
• Imaging Studies in Metastatic Urogenital Cancer Patients Undergoing Systemic Therapy: Recommendations of a Multidisciplinary Consensus Meeting of the Association of Urological Oncology of the German Cancer Society

  2010cites this paper
• Clinical impact of (18)F-FDG PET in management of patients with renal cell carcinoma.

  2010cites this paper